April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Inhibition of Corneal Neovascularization With a New Antiangiogenic Recombinant Protein
Author Affiliations & Notes
  • J.-L. Bourges
    Ophthalmology, Hotel-Dieu Hospital, Paris Descartes University, APHP, INSERM CRC UMRS872-17, Paris, France
  • J.-M. Ortiz Egea
    Equipe 17, Centre de Recherche des Cordeliers, UMRS 872, INSERM, Paris, France
  • M.-C. Naud
    Equipe 17, Centre de Recherche des Cordeliers, UMRS 872, INSERM, Paris, France
  • N. Minet
    Research and Development, Laboratoire Sisène, Paris, France
  • M. Berdugo-Polack
    Equipe 17, Centre de Recherche des Cordeliers, UMRS 872, INSERM, Paris, France
  • L. Leconte
    Research and Development, Laboratoire Sisène, Paris, France
  • L.-M. Bachelot
    Research and Development, Laboratoire Sisène, Paris, France
  • F. F. Behar-Cohen
    Ophthalmology, Hotel-Dieu Hospital, Paris Descartes University, APHP, INSERM CRC UMRS872-17, Paris, France
  • Footnotes
    Commercial Relationships  J.-L. Bourges, None; J.-M. Ortiz Egea, None; M.-C. Naud, None; N. Minet, NM, E; M. Berdugo-Polack, None; L. Leconte, LL, E; L.-M. Bachelot, LMB, P; F.F. Behar-Cohen, None.
  • Footnotes
    Support  Théa Pharmaceutic laboratory, Clermont-Ferrand, France
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 2809. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J.-L. Bourges, J.-M. Ortiz Egea, M.-C. Naud, N. Minet, M. Berdugo-Polack, L. Leconte, L.-M. Bachelot, F. F. Behar-Cohen; Inhibition of Corneal Neovascularization With a New Antiangiogenic Recombinant Protein. Invest. Ophthalmol. Vis. Sci. 2010;51(13):2809.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : to inhibit proliferation of new vessels growing across cornea with a novel antiangiogenic recombinant 55 kDa protein NOV (Sisene, France) and its C terminal truncation 26.4 kDA NOVCter (Sisene, France).

Methods: : New vessels were induced on Lewis rat corneas by intralamellar insertion of 0.2 mm elevax implant loaded with LPS (Sigma-Aldricht, France). Implanted rats were randomly assigned to the following subconjunctival treatment (10 µl/injection) groups NOV1 and NOV2 respectively receiving 1 and 2 µg of native NOV protein (n=5 and 7 eyes), NOVCter receiving 2 µg of native NOVCter protein (n=6 eyes), and PBS control (n=8 eyes). New vessels were quantified after 6 and 8 days on pictures by two masked observators grading (0 to 3) vessels’density, diameter and spreading. After sacrifice at D8, corneas were stained with lectin and further analyzed with confocal microscope.

Results: : At D8, the mean total scores ±SD for density, diameter and vessels’ speading area were were respectively 2.66±0.5, 2.66±0.5and 2.8±0.4 for the PBS group, 2.36±0.8, 2.8±0.4, 2.27±0.8 and 1.9±0.8, 1.8±0.9, 2.1±0.7 for NOV1 and NOV2 and 2.27±0.8, 2.27±0.8, 2.27±0.9 for NOVCter. Vessels growing on corneas from group NOV2 were significantly reduced versus PBS (P<0.001). Clinical observations were confirmed with 3D concofal microscope examination.

Conclusions: : Recombinant NOV protein is a promising treatment to limit induced neovascularization. A dose effect is observed and might explain NOVCter results

Keywords: cornea: clinical science • anterior segment • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×